Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up - What's Next?

Key Points

• Hikma shares gapped up from $16.40 to $17.2950 at the open but on very light volume (167 shares) and still trade below the 50‑day ($20.12) and 200‑day ($21.41) moving averages.
• Barclays downgraded the stock to a "strong sell" (Jan 6), leaving mixed analyst views overall (one Buy, one Sell, consensus "Hold").
• Balance-sheet highlights show low leverage (debt/equity 0.33) but tight liquidity (current ratio 1.24, quick ratio 0.72), indicating limited short‑term cushion.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $16.40, but opened at $17.2950. Hikma Pharmaceuticals shares last traded at $17.2950, with a volume of 167 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Barclays downgraded shares of Hikma Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 6th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold".

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.24 and a quick ratio of 0.72. The stock has a 50 day simple moving average of $20.12 and a 200 day simple moving average of $21.41.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company's three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.